Our company obtained regulatory approval in 2021 and submitted the approval clearance document for PureLift, which was reimbursed in 2022, but the approval has since expired. Domestic supply has been discontinued, and delays in establishing a new manufacturing system have occurred. Meanwhile, development of endoscopic mucosal injection materials based on self-assembled peptide technology is being promoted for the U.S. market. Shipping in the Japanese market is limited, with no impact on performance.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7777","jir_company_name":"Three D Matrix Co., Ltd.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-06-26","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/7777-20260626-01.pdf","jir_short_summary":"Our company obtained regulatory approval in 2021 and submitted the approval clearance document for PureLift, which was reimbursed in 2022, but the approval has since expired. Domestic supply has been discontinued, and delays in establishing a new manufacturing system have occurred. Meanwhile, development of endoscopic mucosal injection materials based on self-assembled peptide technology is being promoted for the U.S. market. Shipping in the Japanese market is limited, with no impact on performance.","jir_summary":"### Overview of Business Activities\nOur company obtained regulatory approval for PureLift in 2021, and reimbursement was approved in 2022. Subsequently, we submitted an approval clearance document, leading to expiration of the regulatory approval. Domestic supply has been discontinued, and there are delays in establishing a new manufacturing system. Meanwhile, we are continuing sales promotion and product development for endoscopic mucosal injection materials based on self-assembling peptide technology, which are considered to have high business potential in the U.S. market. In Japan, shipments are limited, and there is no impact on performance.\n\n### Future Outlook and Impact on Shareholders\nWhile the delay in establishing domestic manufacturing systems continues to result in supply discontinuation, we are focusing on product development and sales expansion for the U.S. market. Based on development progress and overseas approval status in Japan, future business strategies will be considered. The approval clearance submission will not have a short-term impact on financial results, and we will continue to expand overseas markets and develop new products with the goal of long-term growth.","jir_financial_highlights":"Expiration of regulatory approval: Unknown (Expired due to submission of approval clearance document)\nDiscontinuation of domestic supply: Unknown (Supply discontinued)\nBusiness prospects in the U.S. market: High (Ongoing development promotion)","jir_category":"","jir_hashtags":"#ThreeDMatrixCoLtd, #IR, #JapanStocks","jir_key_figures":"Regulatory approval expiration notice submitted\nDomestic supply discontinued\nDevelopment of products for the U.S. market underway","jir_meta_title":"\u3010Three D Matrix Co., Ltd.\u3011Discontinuation of Domestic Supply and U.S. Expansion | June 2026","jir_meta_description":"Three D Matrix Co., Ltd. has submitted the approval clearance document for PureLift and discontinued domestic supply. Development of new products for the U.S. market is ongoing. Details are explained.","jir_og_title":"\u3010Three D Matrix\u3011Discontinuation of Domestic Supply and U.S. Expansion | June 2026","jir_og_description":"An explanation of the background of domestic supply discontinuation and new product development for the U.S. market. Also includes long-term business outlook and impact on shareholders.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56804,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-71713","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n